Evidence for Enhanced Intestinal Absorption of Digoxin by P-Glycoprotein Inhibitors

被引:10
|
作者
Valizadeh, Hadi [2 ]
Mehtari, Maryam [3 ]
Zakeri-Milani, Parvin [1 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Drug Appl Res Ctr, Tabriz, Iran
关键词
Digoxin; Macrolides; Efflux; Intestinal permeability; P-glycoprotein; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; MACROLIDE ANTIBIOTICS; RAT; PERMEABILITY; TRANSPORTER; EXSORPTION;
D O I
10.4314/tjpr.v11i6.10
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of macrolides as P-glycoprotein inhibitors on the level of intestinal absorption of digoxin. Methods: Jejunal segments of anaesthetized rats were cannulated and perfused by digoxin in phosphate buffered saline (PBS) at 37 degrees C in the presence or absence of macrolides (erythromycin and clarithromycin). Samples were obtained from outlet tubing at different time points and digoxin concentration assayed. The effective permeability of the drug was calculated after analyzing the samples using reverse-phase HPLC method. Results: Digoxin effective permeability was in the range of 0.24 +/- 0.02 x 10(-4) to 0.32 +/- 0.06 x 10(-4) cm/sec for the control group. The macrolides significantly (p < 0.05) increased intestinal transport of digoxin, with digoxin in the presence of 150 mu M of each macrolide in the range 0.42 +/- 0.08 x 10(-4) to 0.52 +/- 0.07 x 10(-4) cm/sec. However, no significant difference (p > 0.05) was observed between the effects of the two macrolides. Conclusion: The probable explanation for digoxin-macrolide interaction is inhibition of intestinal P-glycoprotein-mediated efflux of digoxin which leads to increased digoxin intestinal absorption.
引用
收藏
页码:939 / 945
页数:7
相关论文
共 50 条
  • [1] Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
    Westphal, K
    Weinbrenner, A
    Giessmann, T
    Stuhr, M
    Franke, G
    Zschiesche, M
    Oertel, R
    Terhaag, B
    Kroemer, HK
    Siegmund, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (01) : 6 - 12
  • [2] Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs
    Kono, Yusuke
    Kawahara, Iichiro
    Shinozaki, Kohei
    Nomura, Ikuo
    Marutani, Honoka
    Yamamoto, Akira
    Fujita, Takuya
    PHARMACEUTICS, 2021, 13 (03)
  • [3] The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats
    Sababi, M
    Borgå, O
    Hultkvist-Bengtsson, U
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (01) : 21 - 27
  • [4] Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in Mice
    Renaud, Helen J.
    Klaassen, Curtis D.
    Csanaky, Ivan L.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (03) : 366 - 369
  • [5] The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    Greiner, B
    Eichelbaum, M
    Fritz, P
    Kreichgauer, HP
    Von Richter, O
    Zundler, J
    Kroemer, HK
    JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02): : 147 - 153
  • [6] Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin
    Ghanem, Carolina I.
    Gomez, Paula C.
    Arana, Maria C.
    Perassolo, Maria
    Carpini, Griselda Delli
    Luquita, Marcelo G.
    Veggi, Luis M.
    Catania, Viviana A.
    Bengochea, Laura A.
    Mottino, Aldo D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (03): : 1146 - 1152
  • [7] Intestinal P-glycoprotein inhibitors, benzoxanthone analogues
    Chae, Song Wha
    Lee, Jaeok
    Park, Jung Hyun
    Kwon, Youngjoo
    Na, Younghwa
    Lee, Hwa Jeong
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, 70 (02) : 234 - 241
  • [8] Modeling the Kinetics of Digoxin Absorption: Enhancement by P-Glycoprotein Inhibition
    Weiss, Michael
    Sermsappasuk, Pakawadee
    Siegmund, Werner
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (03): : 381 - 387
  • [9] Human intestinal P-glycoprotein activity estimated by the model substrate digoxin
    Andersen, V
    Larsen, UL
    Olesen, LH
    Nyvold, CG
    Eriksen, J
    Jakobsen, P
    Autrup, H
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (02) : 197 - 197
  • [10] Human intestinal P-glycoprotein activity estimated by the model substrate digoxin
    Larsen, U. L.
    Olesen, L. Hyldahl
    Nyvold, C. Guldborg
    Eriksen, J.
    Jakobsen, P.
    Ostergaard, M.
    Autrup, H.
    Andersen, V.
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2007, 67 (02): : 123 - 134